Myl2-Associated Congenital Fiber-Type Disproportion And Cardiomyopathy With Variants In Additional Neuromuscular Disease Genes; The Dilemma Of Panel Testing

Next-generation sequencing has led to transformative advances in our ability to diagnose rare diseases by simultaneously sequencing dozens, hundreds, or even entire genomes worth of genes to efficiently identify pathogenic mutations. These studies amount to multiple hypothesis testing on a massive scale and not infrequently lead to discovery of multiple genetic variants whose relative contributions to a patient's disease are unclear. Panel testing, in particular, can be problematic because each of the many genes being sequenced might represent a plausible explanation for a given case. Weperformed targeted gene panel analysis of 43 established neuromuscular disease genes in a patient with congenital fibertype disproportion (CFTD) and fatal infantile cardiomyopathy. Initial review of variants identified changes in four genesthat could beconsidered relevant candidates to cause this child's disease. Further analysis revealed that two of these are likely benign, but a homozygous frameshift variant in the myosin light chain 2 gene, MYL2, and a heterozygous nonsense mutation in the nebulin gene, NEB, metcriteria to be classified as likely pathogenic or pathogenic. Recessive MYL2 mutations are a rare cause of CFTD associated with both skeletal and cardiomyopathy, whereas recessive NEB mutations cause nemaline myopathy. Although the proband's phenotype is likely largely explained by the MYL2 variant, the heterozygous pathogenic NEB variant cannot be ruled out as a contributing factor. This case illustrates the complexity when analyzing large numbers of variants fromtargeted gene panels in which each of the genes might plausibly contribute to the patient's clinical presentation.